Boston Scientific (BSX) Cash from Financing Activities (2009 - 2026)

Boston Scientific has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$260.0 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$260.0 million, down 211.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$888.0 million (down 285.77% YoY), and the FY2025 annual result was -$395.0 million, down 121.78% from the prior year.
• Cash from Financing Activities came in at -$260.0 million for Q1 2026 at Boston Scientific, down from -$184.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.6 billion in Q1 2024 to a low of -$344.0 million in Q2 2022.
• The 5-year median for Cash from Financing Activities is $1.0 million (2022), against an average of $36.2 million.
• Across the five-year window, Cash from Financing Activities slumped 17300.0% in 2022 and soared 2373.91% in 2024, its largest moves.
• Boston Scientific's Cash from Financing Activities stood at $1.0 million in 2022, then soared by 1400.0% to $15.0 million in 2023, then surged by 1326.67% to $214.0 million in 2024, then plunged by 185.98% to -$184.0 million in 2025, then sank by 41.3% to -$260.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$260.0 million (Q1 2026), -$184.0 million (Q4 2025), and -$104.0 million (Q3 2025), per Business Quant data.